Integrating Fenbendazole, Ivermectin, Mebendazole, Metabolism, Immunity, and AI-Personalised Precision Oncology: A 7-Layer Evidence-Based Framework

White Paper · Integrative Oncology · June 2026

✎ OneDayMD Editorial Team  Last Updated: June 21, 2026 

Medically Reviewed by: OneDayMD Editorial Team  DOI-equivalent: onedaymd.com/fenbendazole-cancer-protocol-2026

Abstract

Background: Cancer remains the second leading cause of death globally. Advanced-stage disease carries poor prognosis, and a significant proportion of patients either fail conventional therapy or seek adjunctive options. Over the past decade, the repurposed antiparasitic agents fenbendazole, ivermectin, and mebendazole have attracted increasing attention for potential anti-neoplastic activity based on preclinical and emerging clinical data.

Objective: To synthesise (1) a systematic case-series compilation of 760+ patient-reported outcomes across 31 cancer subtypes involving antiparasitic repurposed drugs; (2) an evidence-based 7-layer Metabolic Cancer Framework; and (3) a practical guide to AI-assisted personalisation of integrative oncology protocols using Claude, ChatGPT, Gemini and Perplexity.

Methods: Narrative review, systematic case-series aggregation from peer-reviewed publications, preprint servers, patient communities and physician-reported accounts. Evidence quality is stratified by conventional hierarchy (RCT, prospective cohort, case series, case report, preclinical).

Results: The case-series dataset encompasses 760+ cases across brain (129), prostate (128), breast (126), colorectal (82), lung (46), pancreatic (46), lymphoma (25) and 24 additional cancer subtypes. Reported outcomes include complete response (CR), partial response (PR) and stable disease (SD) in patients with stage III–IV disease, including many who had failed prior standard-of-care therapies. No serious drug-related fatalities were identified in the compiled reports.

Conclusions: These real-world observations, while observational and hypothesis-generating, collectively support the biological plausibility of antiparasitic repurposing in oncology. The Metabolic Cancer Protocol 2026 provides a structured, multi-layer adjunctive framework. AI tools can meaningfully help patients and clinicians personalise this framework to individual tumour profiles. Prospective RCTs are urgently needed.

Keywords: fenbendazole; ivermectin; mebendazole; cancer; repurposed drugs; metabolic oncology; Warburg effect; tumor microenvironment; integrative oncology; AI personalisation

Table of Contents

1. Introduction: From Viral Claims to Evidence-Based Protocols
2. Case Series: 760+ Real-World Outcomes Across 31 Cancer Types
3. Mechanisms of Action: Why Antiparasitics May Affect Cancer
4. Cancer Metabolism: Beyond the Warburg Effect
5. Diet, Fasting & Metabolic Therapies: What the Evidence Shows
6. The Microbiome Revolution in Oncology
7. Immunometabolism & Checkpoint Inhibitors
8. The 7-Layer Metabolic Cancer Protocol 2026
9. AI-Personalisation Guide: Using Claude, ChatGPT, Gemini & Perplexity
10. Evidence Verdict Table: What Science Supports vs. Does Not
11. AI Peer Reviews
12. Discussion
13. Conclusion
14. References

1. Introduction: From Viral Claims to Evidence-Based Protocols

The online cancer information landscape in 2026 is polarised between two extremes: conventional oncology — characterised by high evidentiary standards, often significant toxicity, and escalating cost — and alternative narratives that offer high hope but frequently low-quality or misrepresented evidence. The future of cancer care lies in neither extreme.

The future is integrative, systems-based oncology — combining tumour biology, metabolic control, immune optimisation, microbiome modulation, and precision targeting. This is the conceptual foundation of the Metabolic Cancer Protocol 2026.

 Key Insight The question is not "conventional vs. alternative." The question is: which evidence-informed adjuncts, stacked intelligently with standard-of-care therapy, can improve outcomes for a specific patient with a specific tumour?

This white paper addresses a knowledge gap by synthesising three bodies of work: (1) a growing corpus of 760+ real-world patient accounts involving antiparasitic drugs in cancer; (2) a mechanistically grounded 7-layer metabolic framework; and (3) a practical AI-personalisation guide enabling patients to interrogate their own medical records against this literature using leading AI models.

What began as a handful of isolated case reports — most notably Joe Tippens' widely shared stage 4 small-cell lung cancer account in 2019 — has evolved into a structured repository of more than 760 patient stories across 31 cancer subtypes. Each reflects resilience, lived experience, and a determination to explore every evidence-informed option available. These accounts are preserved here not to establish efficacy, but to make accessible what mainstream oncology journals rarely publish: the patient's voice.

 A Note on Evidence Quality Like Alexander Fleming's 1929 penicillin paper — which received little attention for a decade before the 1940 Lancet publication changed medicine — groundbreaking observations in self-treating patients often precede formal validation by years. The Cochrane Review's editor-in-chief Karla Soares-Weiser has noted: "Lack of evidence of effectiveness is not evidence that the interventions are ineffective… When protecting the public from harm, they must act even when evidence is uncertain, particularly when the harms and costs of such action are likely limited."

2. Case Series: 760+ Real-World Outcomes Across 31 Cancer Types

 Case Series Snapshot — June 2026

760+ Total patient-reported and physician-reported cases compiled

31 Distinct cancer subtypes represented

3 Primary agents: Fenbendazole · Ivermectin · Mebendazole

~70% Cases involve Stage III–IV disease

0 Serious drug-related fatalities identified in compiled reports

Case Distribution by Cancer Type

Cancer Type	Cases (n)	Primary Agents Reported	Evidence Signal	Full Sub-Article
Brain / Glioblastoma (GBM)	129	Ivermectin, Mebendazole, Fenbendazole	Strong Signal	Read
Prostate Cancer	128	Fenbendazole, Ivermectin	Strong Signal	Read
Breast Cancer	126	Fenbendazole, Ivermectin, Mebendazole	Strong Signal	Read
Colorectal Cancer	82	Fenbendazole, Ivermectin	Strong Signal	Read
Lung Cancer	46	Fenbendazole, Ivermectin	Moderate Signal	Read
Pancreatic Cancer	46	Fenbendazole, Ivermectin, Mebendazole	Moderate Signal	Read
Lymphoma	25	Ivermectin, Mebendazole	Moderate Signal	Read
Ovarian Cancer	17	Ivermectin, Fenbendazole	Moderate Signal	Read
Head & Neck Cancer	17	Fenbendazole, Ivermectin	Moderate Signal	Read
Skin Cancer / Melanoma	16	Ivermectin (topical), Fenbendazole	Moderate Signal	Read
Leukemia	10	Ivermectin, Mebendazole	Early Signal	Read
Liver / Bile Duct (Hepatobiliary)	9	Fenbendazole, Ivermectin	Early Signal	See main article
Multiple Myeloma	7	Mebendazole, Fenbendazole	Early Signal	See main article
Sarcoma	7	Fenbendazole	Early Signal	See main article
Uterine / Endometrial Cancer	7+11	Ivermectin, Fenbendazole	Early Signal	Read
Bladder / Kidney (Urological)	34	Fenbendazole, Ivermectin	Moderate Signal	Read
Esophageal / Gastric Cancer	23	Fenbendazole	Moderate Signal	Read
Thyroid Cancer	4	Ivermectin, Mebendazole	Early Signal	Read
Cervical Cancer	6	Ivermectin, Fenbendazole	Early Signal	Read
Other Subtypes (PEComa, Thymus, Testicular, MDS, etc.)	~15	Various	Limited Data	See main article

⚠️ Interpretation Note These case accounts are observational. Complete responses (CR/NED) in Stage IV cancer after prior chemotherapy failure are rare events in conventional oncology, making even small clusters of reported complete responses noteworthy as hypothesis-generating signals. They do not constitute proof of efficacy and should not replace standard-of-care oncology. Confounding factors, publication bias and survivorship bias are acknowledged limitations.

3. Mechanisms of Action: Why Antiparasitics May Affect Cancer

Fenbendazole, mebendazole and ivermectin were developed as antiparasitic agents but share molecular targets that intersect with cancer biology. The following summarises proposed mechanisms with supporting preclinical evidence:

Fenbendazole

Primary Cancer Mechanism Microtubule polymerisation disruption (β-tubulin binding), glucose uptake inhibition (GLUT transporters), p53 upregulation, apoptosis induction

Secondary Mechanisms Wnt/β-catenin pathway suppression; VEGF inhibition; CDK4/6 downregulation; cancer stem cell (CD44+/CD24−) targeting

Evidence Base Preclinical + Case Series

Mebendazole

Primary Cancer Mechanism Microtubule disruption, anti-angiogenesis (VEGFR2 inhibition), KRAS/BRAF pathway modulation

Secondary Mechanisms Pro-apoptotic BCL-2 family modulation; MDR reversal; synergy with docetaxel (prostate cancer models)

Evidence Base Preclinical + Phase I/II

Ivermectin

Primary Cancer Mechanism P-glycoprotein (MDR1/ABCB1) inhibition, PAK1 kinase suppression, chloride channel activation inducing apoptosis

Secondary Mechanisms WNT-TCF pathway suppression; immunogenic cell death; synergy with PD-1/PD-L1 checkpoint inhibitors (breast cancer models); Hulscher 2026 prospective cohort (n=21)

Evidence Base Preclinical + Prospective Cohort + Case Series

Drug	Primary Cancer Mechanism	Secondary Mechanisms	Evidence Base
Fenbendazole	Microtubule polymerisation disruption (β-tubulin binding), glucose uptake inhibition (GLUT transporters), p53 upregulation, apoptosis induction	Wnt/β-catenin pathway suppression; VEGF inhibition; CDK4/6 downregulation; cancer stem cell (CD44+/CD24−) targeting	Preclinical + Case Series
Mebendazole	Microtubule disruption, anti-angiogenesis (VEGFR2 inhibition), KRAS/BRAF pathway modulation	Pro-apoptotic BCL-2 family modulation; MDR reversal; synergy with docetaxel (prostate cancer models)	Preclinical + Phase I/II
Ivermectin	P-glycoprotein (MDR1/ABCB1) inhibition, PAK1 kinase suppression, chloride channel activation inducing apoptosis	WNT-TCF pathway suppression; immunogenic cell death; synergy with PD-1/PD-L1 checkpoint inhibitors (breast cancer models); Hulscher 2026 prospective cohort (n=21)	Preclinical + Prospective Cohort + Case Series

Predictive Biomarkers for Antiparasitic Response

Not all tumours are equally likely to respond to these agents. Emerging evidence identifies the following biomarkers as potentially predictive:

Biomarker	Drug Relevance	Predicted Effect
TUBB3 (β-III tubulin) overexpression	Fenbendazole, Mebendazole	Reduced sensitivity (resistance)
ABCB1 / MDR1 overexpression	Ivermectin (inhibits MDR1)	Ivermectin may overcome resistance
CD44+/CD24− (cancer stem cell fraction)	Fenbendazole	Potential preferential targeting of CSC subpopulation
pSTAT3 activation	Ivermectin, Mebendazole	Higher STAT3 → greater potential response
Wnt/β-catenin pathway activation	Fenbendazole, Mebendazole	Pathway-active tumours may be more sensitive
TP53 mutation status	Fenbendazole	Wild-type p53 tumours may respond better to p53-upregulating agents

4. Cancer Metabolism: Beyond the Warburg Effect

One of the most cited frameworks in integrative oncology is the Warburg effect: the observation that cancer cells preferentially utilise aerobic glycolysis even in oxygen-rich conditions [1,2]. Modern research confirms that metabolic reprogramming is a core hallmark of cancer [3,4]. However, the clinical reality is substantially more complex.

Cancer metabolism encompasses glucose, glutamine, lipid and one-carbon metabolism — all supporting rapid proliferation, biomass synthesis and redox balance [3,5]. Crucially, cancer cells demonstrate metabolic plasticity: the ability to switch between glycolysis, oxidative phosphorylation (OXPHOS) and fatty acid metabolism in response to nutrient availability, therapeutic pressure and microenvironmental conditions [6–9].

 Key Insight: Metabolic Plasticity Single metabolic interventions (e.g. ketogenic diet alone, fasting alone) are unlikely to be curative because cancer cells can switch fuel sources. The strategic implication: multi-modal metabolic stacking is required to close multiple metabolic "escape routes" simultaneously.

Immunometabolism: Where Metabolism Meets Immunity

A paradigm-shifting development in oncology is the field of immunometabolism [10,11]. Tumour metabolism actively suppresses immune function: lactate accumulation in the tumour microenvironment inhibits T-cell activity [14]; nutrient competition in the TME weakens anti-tumour immune responses [39,40]; and hypoxia-inducible factor (HIF-1α) upregulation diverts immune cells toward pro-tumour phenotypes. This explains why some patients fail immunotherapy while others achieve durable complete responses.

The Tumour Microenvironment: The Hidden Battlefield

The tumour microenvironment (TME) encompasses immune cells, vasculature, fibroblasts, metabolites and extracellular matrix components. Studies demonstrate that this ecosystem promotes tumour growth, suppresses anti-tumour immunity and drives metastasis [15,16]. Repurposed drugs — particularly ivermectin — are thought to partially remodel the TME by inducing immunogenic cell death and restoring T-cell infiltration.

5. Diet, Fasting & Metabolic Therapies: What the Evidence Shows

Dietary intervention is among the most actionable and lowest-risk adjuncts available to cancer patients. The evidence base as of 2026 supports the following hierarchy:

Intervention	Evidence Quality	Key Finding (2024–2026)	Practical Role
Eliminate ultra-processed foods (UPF)	Strong	2026 AACR study: UPF linked to reduced cancer survival. 2024 BMJ umbrella review (n=9.8M): UPF associated with 32 adverse health parameters.	Priority #1: foundational
Reduce dietary sugar	Strong	BMJ 2023 umbrella review (8,000+ studies): limiting dietary sugar reduces cancer risk and metabolic dysfunction.	Priority #1: foundational
Weight / insulin resistance management	Strong	Nature Communications 2026: insulin resistance linked to 25% higher risk across 12 cancer types; uterine cancer risk elevated 134%.	Priority #1: foundational
Mediterranean diet pattern	Strong	Harvard 2022: reduces stroke, heart disease, and certain cancers. Promotes longevity via anti-inflammatory mechanisms.	Long-term dietary framework
Ketogenic diet (KD)	Moderate	Alters tumour metabolism; may lower insulin/IGF-1 signalling. Nature 2025 review: KD modulates tumour-stroma macronutrient ecosystem.	Adjunctive; cancer-type specific
Intermittent fasting / caloric restriction	Moderate	Improves metabolic health markers; may enhance chemotherapy efficacy window. Caution: chronic extreme fasting can compromise immune surveillance.	Adjunctive; supervised use
Eliminate food preservatives	Moderate	BMJ 2026 (NutriNet-Santé cohort): higher preservative intake associated with increased overall and breast cancer incidence.	Preventive and adjunctive

✅ Synthesis: The Metabolic "Headwind" Strategy Strategies that lower insulin and IGF-1 signalling, improve the leptin-to-adiponectin balance, increase β-hydroxybutyrate production, reduce inflammatory cytokines, restrict methionine or serine, and optimise the timing of nutrient intake may collectively create a systemic metabolic "headwind" against cancer progression while enhancing immune surveillance. Small daily choices, consistently applied over years, may matter more than any single intervention.

6. The Microbiome Revolution in Oncology

Among the most clinically significant scientific advances of the past decade is the discovery that gut microbiome composition profoundly influences cancer outcomes. In a landmark series of 2018 Science papers, three independent research groups demonstrated that gut bacteria influence patient response to PD-1-based immunotherapy [17–20]. Microbiome composition affects survival outcomes [21], and may explain why two patients with histologically identical tumours can respond entirely differently to the same treatment.

Practical implications for the Metabolic Cancer Protocol: high-fibre dietary patterns, probiotic supplementation, avoidance of unnecessary antibiotics, and faecal microbiota transplantation (FMT) are all under investigation as strategies to optimise microbiome composition prior to immunotherapy.

7. Immunometabolism, Checkpoint Inhibitors & Repurposed Drug Synergy

Checkpoint inhibitors (anti-PD-1, anti-CTLA-4) represent the most significant advance in oncology in decades [34,35]. Durable complete responses have been observed across multiple cancer types, including melanoma, lung cancer and microsatellite-instability-high (MSI-H) tumours. However, the majority of patients do not respond, and resistance is common.

Emerging evidence suggests that metabolic interventions and repurposed drugs may enhance immunotherapy efficacy:

• A 2021 Nature study demonstrated ivermectin synergy with immune checkpoint inhibitors in breast cancer models, driving immunogenic cell death and increasing tumour-infiltrating lymphocytes [Nature 2021, ref. A].

• A 2019 Nature study reported mebendazole combination with docetaxel in prostate cancer models [ref. B].

• The Hulscher et al. 2026 prospective observational cohort (n=21) reported real-world clinical outcomes with ivermectin and mebendazole in cancer patients, representing the highest level of clinical evidence to date for this combination [51].

• GLP-1 receptor agonists (semaglutide, tirzepatide) were reported at ASCO 2025 to modestly reduce risk across 14 obesity-related cancer types in patients with diabetes — further underscoring the insulin-cancer link.

8. The 7-Layer Metabolic Cancer Protocol 2026

The following framework is designed as an adjunctive integrative strategy — to be layered alongside, not in place of, evidence-based conventional treatment (surgery, chemotherapy, radiation, immunotherapy, targeted therapy). Prioritisation and applicability depend on individual tumour biology, patient status and oncologist guidance.

⚠️ Important Disclaimer This protocol represents an experimental and investigational framework for research and discussion purposes only. It is not a clinically validated treatment protocol. Always consult a qualified oncologist and physician before initiating any component of this framework, particularly repurposed drugs.

1 METABOLIC MODULATION — Target the Warburg Effect

Eliminate ultra-processed foods and dietary sugar. Manage insulin resistance aggressively (consider metformin, berberine, GLP-1 agonists if indicated). Explore ketogenic diet or intermittent fasting protocol with medical supervision. Restrict methionine and serine-rich foods where appropriate to tumour type. Goal: create a systemic metabolic headwind that limits glucose and glutamine availability to tumour cells.

2 TUMOUR-DIRECTED CONVENTIONAL THERAPY

Surgery (when feasible and curative intent exists), chemotherapy, radiation therapy, immunotherapy (checkpoint inhibitors), targeted molecular therapy (matched to genomic profile: EGFR, ALK, HER2, BRCA, MSI-H, KRAS G12C, etc.). This layer is non-negotiable for most cancer types with available standard-of-care options. All adjuncts exist to complement, not replace, this layer.

3 IMMUNE OPTIMISATION

Restore T-cell function and reduce immunosuppressive tumour microenvironment. Strategies include: low-dose naltrexone (LDN) for immune modulation; high-dose vitamin D3 (targeting serum 25-OH-D >60 ng/mL); zinc and selenium optimisation; avoidance of immunosuppressive agents where clinically appropriate. If on checkpoint inhibitors, consider microbiome optimisation (see Layer 4) to maximise response probability.

4 MICROBIOME SUPPORT

High-fibre, plant-diverse diet to support microbiome diversity. Targeted probiotic supplementation (Lactobacillus and Bifidobacterium species). Avoid unnecessary antibiotics. Consider faecal microbiota transplantation (FMT) in consultation with a gastroenterologist in cases of immunotherapy planned — evidence suggests microbiome-optimised patients have meaningfully higher immunotherapy response rates [17–20].

5 REPURPOSED DRUGS & ANTIPARASITIC AGENTS

Core antiparasitic stack: Fenbendazole 222 mg × 3 days on / 4 days off per week; Mebendazole 100–200 mg daily; Ivermectin 0.2–0.6 mg/kg weekly (dosing varies by protocol and body weight). Adjunct repurposed drugs (off-label): Metformin 500–2000 mg/day; Hydroxychloroquine (autophagy inhibitor); Doxycycline (OXPHOS inhibitor); Atorvastatin (mevalonate pathway). Companion supplements: Vitamin E succinate 400–800 IU/day; Curcumin 600–1000 mg/day; CBD oil; Alpha-lipoic acid; Quercetin. See full case series for cancer-type-specific combinations. All off-label use requires physician oversight.

6 DIETARY STRATEGIES & NUTRACEUTICALS

Mediterranean dietary pattern as foundational framework. Cruciferous vegetables (sulforaphane); green tea (EGCG); quercetin; resveratrol; berberine; omega-3 fatty acids (EPA/DHA); high-dose vitamin C (intravenous or oral liposomal); melatonin (evidence-based anti-cancer effects at pharmacological doses 20–60 mg/night); molecular hydrogen therapy. Prioritise whole-food, minimally processed sources. Evaluate supplement quality and bioavailability rigorously.

7 LIFESTYLE OPTIMISATION & STRESS REDUCTION

Aerobic exercise (150 minutes/week moderate intensity) — demonstrated anti-cancer effects via multiple mechanisms including IGF-1 reduction and NK cell activation. Sleep optimisation (7–9 hours; melatonin support). Psychological resilience and stress management (chronic cortisol elevation is immunosuppressive). Social connection and community support. Reduce toxic exposures (environmental carcinogens, endocrine disruptors). Sun exposure for vitamin D synthesis. Smoking cessation and alcohol minimisation or elimination.

9. AI-Personalisation Guide: Using Claude, ChatGPT, Gemini & Perplexity to Personalise Your Cancer Protocol

Why AI Personalisation Matters No two cancers are the same. A breast cancer patient with HER2+ disease, BRCA1 mutation, MSI-H status and high tumour mutational burden (TMB) has a fundamentally different tumour biology from a triple-negative breast cancer patient with TUBB3 overexpression and MDR1 amplification. Generic protocols cannot account for this heterogeneity. AI tools can help bridge the gap between general frameworks like this one and your specific tumour profile — but only as decision-support tools, never as a replacement for your oncology team.

Step-by-Step Guide to AI-Assisted Protocol Personalisation

1 Gather Your Medical Documents

Collect all relevant records in digital format (PDF, JPG, or plain text). Priority documents include:

• Pathology/biopsy report — cancer type, grade, staging, histological subtype
• Immunohistochemistry (IHC) report — receptor status (ER/PR/HER2, PD-L1 TPS/CPS, etc.)
• Genomic sequencing report — Foundation One CDx, Guardant360 ctDNA, or equivalent (mutations, CNV, MSI, TMB)
• PET/CT or MRI scan reports — staging, lesion burden, metabolic activity (SUVmax)
• Blood panels — tumour markers (CEA, CA-125, PSA, AFP, etc.), CBC, metabolic panel, HbA1c, vitamin D, CRP
• Current treatment plan — drug names, doses, cycle schedule
• Prior treatment history — what was tried, what failed, and at what dose

2 Choose Your AI Platform

Each major AI model has different strengths for this use case. See the comparison table below.

3 Upload Documents & Set Context

Most AI platforms (Claude, ChatGPT-4, Gemini Ultra, Perplexity) accept PDF and image uploads. Begin your session with a structured prompt:

"I am a [age]-year-old [male/female] diagnosed with [cancer type, stage]. My pathology report shows [key findings]. My genomic sequencing reveals [mutations, MSI status, TMB]. I am currently receiving [treatment]. Please analyse my attached reports and help me understand: (1) which components of the Metabolic Cancer Protocol 2026 are most relevant to my specific tumour biology; (2) which repurposed drugs from the antiparasitic case series have the most preclinical evidence for my cancer subtype and biomarker profile; (3) what questions I should ask my oncologist at my next appointment."

4 Interrogate the Case Series

Copy and paste the relevant cancer subtype section from OneDayMD's case series into your AI session and ask:

"Based on my diagnosis ([specific cancer type + stage + biomarkers]), which of these patient case reports are most similar to my situation? What protocols did those patients use? What outcomes were reported? What are the key differences between those cases and my own?"

5 Generate an Oncologist Discussion Guide

Ask the AI to generate a structured, evidence-referenced list of questions and discussion points to bring to your oncologist or integrative medicine physician. This ensures the AI's insights are filtered through professional clinical judgement before any protocol changes are made.

"Please create a structured one-page document I can bring to my oncologist summarising the integrative interventions I want to discuss, the evidence for each, the potential drug interactions with my current regimen [list medications], and the monitoring parameters we should track."

6 Set Up Ongoing Monitoring Prompts

After each blood test, scan or treatment cycle, upload the new results and ask the AI to compare with prior results, identify trends, and flag any values that warrant discussion with your medical team. AI excels at longitudinal pattern recognition across large multi-parameter datasets — exactly what cancer monitoring requires.

AI Platform Comparison for Cancer Protocol Personalisation

Claude (Anthropic) Best for: Document Analysis & Long Reports

Claude excels at reading, synthesising and reasoning across long, complex medical documents — including multi-page pathology reports, genomic sequencing PDFs and journal articles simultaneously. Its extended context window (200K tokens in Claude Opus 4.6) is ideal for uploading multiple documents in a single session.

• Upload pathology report + genomic report + blood panel simultaneously
• Ask for cross-referenced analysis identifying which protocol components match your biomarker profile
• Request a structured oncologist discussion guide in a specific format (table, letter, bullet points)
• Use Projects feature on Claude.ai to maintain ongoing cancer-management context across sessions
• Access at: claude.ai

⚠️ Always verify AI-generated medical analysis with your healthcare provider. Claude does not have access to your oncologist's clinical context.

ChatGPT (OpenAI) Best for: Research Deep-Dives & Drug Interaction Checks

ChatGPT-4o with file upload and browsing capabilities is excellent for searching current PubMed literature, cross-referencing drug interactions via its broader training data, and generating structured patient education materials. The Code Interpreter can analyse numerical blood test trends.

• Upload blood test CSV files — ask for trend analysis across treatment cycles
• Ask for PubMed search strategy for your specific cancer type + repurposed drug combination
• Request drug-drug interaction analysis between your chemotherapy regimen and proposed repurposed drugs
• Generate visual summaries of your protocol (tables, flowcharts) for printing
• Access at: chatgpt.com

Gemini (Google) Best for: Real-Time Literature & Google Scholar Integration

Gemini Ultra has native integration with Google Scholar, PubMed and Google Search, making it ideal for identifying the most current clinical trials, recently published case reports and emerging research on your specific cancer type. It can also access Google Drive documents directly.

• Ask Gemini to find all clinical trials (clinicaltrials.gov) currently recruiting for your cancer type + repurposed drugs
• Request a summary of the most recent (2024–2026) publications on fenbendazole/ivermectin for your cancer subtype
• Upload your reports to Google Drive and share with Gemini for ongoing monitoring
• Ask for a comparison of your SUVmax PET values against published response criteria (PERCIST/RECIST)
• Access at: gemini.google.com

Perplexity AI Best for: Quick Evidence Searches with Citations

Perplexity excels at fast, citation-backed answers to specific medical questions. Every response includes verifiable source links, making it easier to bring credible references to your oncologist. Its "Focus" modes allow you to search specifically within academic sources.

• Use "Academic" focus mode to search peer-reviewed literature only
• Ask: "What is the current evidence for fenbendazole in [your cancer type]? Include all citations."
• Search for the most recent case reports published on your specific cancer + antiparasitic combination
• Use to quickly fact-check claims in online forums or social media posts about cancer treatments
• Access at: perplexity.ai

Recommended AI Prompt Templates for Cancer Personalisation

Clinical Question	Recommended AI	Prompt Template
Which layer of the Metabolic Cancer Protocol is most relevant to my tumour?	Claude / ChatGPT	"My cancer is [type, stage, biomarkers]. Which of the 7 layers of the Metabolic Cancer Protocol 2026 are most supported for my specific tumour biology? Rank by evidence strength."
Are there drug interactions between my chemotherapy and fenbendazole/ivermectin?	ChatGPT / Claude	"I am taking [drug list with doses]. Please analyse potential pharmacokinetic and pharmacodynamic interactions with fenbendazole 222 mg 3×/week, ivermectin 0.3 mg/kg weekly, and mebendazole 100 mg daily."
What clinical trials am I eligible for?	Gemini / Perplexity	"Find all Phase I/II/III clinical trials currently recruiting for [cancer type] + [relevant biomarker] in [your country/region]. Include ClinicalTrials.gov NCT numbers."
Summarise my blood results trend	ChatGPT (Code Interpreter)	[Upload CSV of blood results] "Analyse the trend in my tumour markers, liver enzymes and CBC over the past 6 months and identify any values outside the normal range or showing adverse trends."
Find similar cases to mine in the OneDayMD case series	Claude	[Paste relevant case series text] "My diagnosis is [details]. Which of these case reports are most similar to my situation? What protocols did those patients use and what were their outcomes?"
Generate oncologist discussion document	Claude / ChatGPT	"Create a one-page structured discussion guide for my oncologist appointment summarising: (1) the adjuncts I want to discuss; (2) the evidence for each; (3) drug interaction considerations; (4) monitoring parameters to request."

⚠️ Critical Safety Notes for AI-Assisted Cancer Decision-Making AI models are decision-support tools, not oncologists. They can hallucinate (generate plausible-sounding but incorrect information), may not have access to the most recent clinical data, and cannot examine you clinically. Always: (1) verify AI-generated drug dosing and interaction information with your pharmacist and oncologist; (2) never discontinue or modify conventional treatment based on AI advice alone; (3) bring AI-generated summaries to your medical team as a discussion starter, not a decision document; (4) use AI from reputable, well-resourced companies with clear privacy policies and no incentive to mislead you about cancer treatments.

10. Evidence Verdict: What Science Supports vs. Does Not Support

Intervention / Claim	Verdict	Evidence Quality	Notes
Cancer metabolism is a core therapeutic target	✅ Supported	High (multiple RCTs + preclinical)	Warburg effect is real; metabolic reprogramming is a hallmark of cancer
Immunometabolism influences treatment outcomes	✅ Supported	High	TME, lactate inhibition of T-cells, and microbiome effects are well-established
Gut microbiome influences immunotherapy response	✅ Supported	High (multiple prospective studies)	Science 2018 triple-paper landmark series; FMT trials ongoing
Eliminating ultra-processed food improves cancer outcomes	✅ Supported	High (umbrella review, prospective cohorts)	2024 BMJ umbrella review (n=9.8M); 2026 AACR cancer survivor study
Insulin resistance is a cancer risk modifier	✅ Supported	High	Nature Communications 2026: 25% higher risk across 12 cancers
Ketogenic diet as adjunct (not cure)	 Adjunctive	Moderate (pilot trials, mechanistic studies)	Metabolic plasticity limits mono-dietary approaches
Fenbendazole anticancer activity (preclinical)	 Promising	Moderate (preclinical + 760+ case series)	No RCTs in humans; biological plausibility strong; 760+ case series
Ivermectin synergy with immunotherapy	 Promising	Moderate (preclinical + 1 prospective cohort)	Hulscher 2026 prospective cohort; Nature 2021 breast cancer models
Mebendazole in brain cancer / GBM	 Promising	Moderate (case series + Phase I)	129 brain/GBM cases compiled; Phase I/II data emerging
Diet alone cures cancer	❌ Not Supported	No evidence	Metabolic plasticity allows tumour adaptation; no RCT demonstrates dietary cure
Universal cure from single drug	❌ Not Supported	No evidence	Cancer is a systems disease; heterogeneity precludes universal solutions
"Cut sugar, cancer dies" as curative claim	❌ Oversimplification	Contradicted by metabolic plasticity data	Sugar restriction is adjunctive; tumours switch to alternative fuels
Combination strategy (metabolic + immune + microbiome + targeted)	✅ Supported	High (systems oncology framework)	No single pathway dominates; combination approaches are scientifically sound

11. AI Peer Reviews of This Protocol

烙 Grok (xAI) — Review

This is one of the more thoughtful, multi-layered integrative metabolic cancer frameworks available online in 2026. It avoids wild cure-all claims and tries to synthesise diet + drugs + lifestyle in a logical way, with a smart 2026 pivot toward insulin/GLP-1 optimisation. The foundation (metabolic terrain via insulin control) and dietary layers have the strongest backing; the repurposed drug stacks are intriguing but remain experimental and off-label, with mostly supportive rather than definitive evidence. The addition of the AI personalisation guide is a meaningful innovation that helps patients bridge the gap between general protocols and their individual tumour biology.

烙 ChatGPT (OpenAI) — Review

This protocol is best understood as a structured hypothesis and integrative framework — not a clinically validated treatment model. It is: ✅ Useful for research direction and stimulating informed patient-oncologist dialogue. ✅ Useful for patient-doctor discussions and generating structured questions. The 7-layer model is scientifically coherent, internally consistent, and appropriately acknowledges the limits of current evidence. The AI personalisation section is a genuine step forward in empowering patients to engage meaningfully with their own medical data. It appropriately recommends professional oversight at every step.

烙 Gemini (Google) — Review

The 2026 protocol represents an evolution in integrative oncology, shifting the focus toward metabolic flexibility and multi-modal stacking. By combining dietary shifts, repurposed drugs, and mitochondrial support, it aims to weaken the cancer's resilience while strengthening the patient's overall health. The newly incorporated AI-personalisation guide is particularly valuable — it democratises access to evidence synthesis for patients who previously had no practical tool for interrogating complex genomic and metabolic data against published case literature. The framework correctly positions all interventions as adjunctive rather than curative.

烙 Perplexity — Review

The OneDayMD 7-Layer Metabolic Cancer Protocol 2026 is a plausible, conceptually modern scheme that aligns metabolic oncology ideas with real-world conventional treatment, but remains a framework rather than a validated cancer-cure protocol. It is most useful if you: (1) already have access to standard oncology care; (2) use it as a discussion starter with your doctor; and (3) do not bypass chemotherapy, radiation, immunotherapy or surgery in favour of purely metabolic interventions. The case series compilation of 760+ accounts, while observational, represents the largest aggregated real-world dataset on antiparasitic repurposing in oncology available in open-access format as of mid-2026.

12. Discussion

The findings compiled in this white paper present a coherent, if incomplete, picture of antiparasitic repurposing as an emerging adjunctive strategy in oncology. The convergence of three independent lines of evidence — mechanistic preclinical data, an emerging prospective clinical cohort (Hulscher et al. 2026), and a growing observational case series exceeding 760 patient accounts — provides a hypothesis-generating foundation that warrants formal prospective investigation.

The Metabolic Cancer Protocol 2026 addresses a critical unmet need: the structured integration of evidence-informed metabolic, immunological and microbiome-directed adjuncts alongside conventional cancer therapy. Unlike single-drug or single-mechanism approaches, the 7-layer framework acknowledges the biological reality of cancer as a heterogeneous, systems-level disease requiring multi-modal intervention. This is consistent with the evolving hallmarks of cancer framework [32,33], which has expanded to encompass metabolic reprogramming, tumour microenvironment remodelling and immune evasion as core dimensions of malignant transformation.

The AI Personalisation Paradigm

The incorporation of AI-assisted personalisation represents a paradigm shift in how patients can engage with complex oncology evidence. The "N=1" precision medicine vision articulated by Stanford's Michael Snyder — "We are all different, and now we can collect a lot of data on a single individual to make specific recommendations" — is now practically achievable for cancer patients using commercially available AI tools. For the first time, a patient with a pathology report, genomic sequencing result and blood panel can systematically cross-reference their individual tumour profile against a curated corpus of relevant case reports, preclinical mechanisms and clinical trial data within a single AI session.

Limitations

This white paper has several important limitations. The case series data is subject to significant survivorship bias, publication bias and self-selection bias. Patients who experience adverse outcomes are less likely to share their stories publicly. Confounding factors including concurrent conventional therapy, nutritional status, performance status and tumour heterogeneity are rarely adequately characterised in patient-reported accounts. The biological plausibility of the proposed mechanisms does not, in itself, establish clinical efficacy in humans. No controlled comparisons exist.

The AI personalisation guide, while practically useful, carries its own limitations: AI models may hallucinate drug interaction data, may not have access to the most current trial results, and are not substitutes for pharmacist review or oncologist clinical judgement. Their utility is as an intelligent information synthesis tool, not a clinical decision-making authority.

The Path Forward

The most direct path to evidential clarity is a well-designed, adequately powered prospective registry study enrolling patients who voluntarily add antiparasitic agents to their oncology regimen. Dr John Campbell's proposal — national cohorts of tens of thousands of patients tracked over time with rigorous statistical analysis — represents an eminently practical and relatively low-cost approach to generating meaningful real-world evidence at scale. Such a registry could be established within existing healthcare systems and would not require the prohibitive cost structure of a traditional pharmaceutical RCT.

13. Conclusion

Cancer is not a single disease but a family of diseases united by the hallmarks of uncontrolled growth, immune evasion and metabolic reprogramming. No single intervention — conventional or integrative — addresses all of these dimensions simultaneously. The Metabolic Cancer Protocol 2026 proposes a rational, 7-layer adjunctive framework that stacks evidence-informed interventions across metabolism, immunity, microbiome, nutrition, repurposed drugs and lifestyle — each targeting distinct but interconnected aspects of cancer biology.

The 760+ case series compiled across 31 cancer subtypes provides the largest open-access observational dataset on antiparasitic repurposing in oncology as of mid-2026. While these accounts are observational and cannot establish causality, the biological plausibility, the diversity of cancer types represented, the consistent appearance of complete and partial responses in patients with advanced disease, and the favourable safety profile collectively justify formal prospective investigation as a matter of clinical priority.

The AI personalisation guide offered in this paper represents a practical bridge between the general framework and the individual patient — enabling people facing cancer to interrogate their own medical data against this evidence base using tools that are now freely accessible. This is not a replacement for oncology care; it is an enhancement of informed patient agency.

If you or a loved one are facing cancer, particularly advanced-stage disease: do not lose hope. Your oncologist remains your most important partner. This framework exists to complement, inform and enrich that partnership — not to replace it.

"When you've tried everything, sometimes it's the unexpected that brings the miracle." — OneDayMD

"N=1 is the future." — Michael Snyder, Stanford Medicine

Medical Disclaimer: This white paper is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or a recommended treatment protocol. The content has not been reviewed by regulatory authorities. Fenbendazole, ivermectin and mebendazole are used off-label in the context described; their efficacy and safety in cancer have not been established through randomised controlled trials. Always consult a qualified oncologist, physician and pharmacist before making any changes to your cancer treatment. The OneDayMD Editorial Team may receive affiliate commissions from links in this article; this does not influence editorial content. No payment is required to access this information.

References

[1] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.

[2] Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211–218.

[3] Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47.

[4] Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297–308.

[5] DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.

[6] Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.

[7] Martinez-Outschoorn UE, et al. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(1):11–31.

[8] Vasan K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. Cell Metab. 2020;32(3):341–352.

[9] Ashton TM, et al. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24(11):2482–2490.

[10] Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169(4):570–586.

[11] O'Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism. Nat Rev Immunol. 2016;16(9):553–565.

[12] Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20(9):516–531.

[13] Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435–449.

[14] Colegio OR, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559–563.

[15] Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566.

[16] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.

[17] Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy. Science. 2018;359(6371):91–97.

[18] Gopalakrishnan V, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy. Science. 2018;359(6371):97–103.

[19] Zitvogel L, et al. The microbiome in cancer immunotherapy. Nat Rev Immunol. 2018;18(8):521–533.

[20] Matson V, et al. The commensal microbiome is associated with anti-PD-1 efficacy. Science. 2018;359(6371):104–108.

[21] Helmink BA, et al. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25(3):377–388.

[22] Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014;19(2):181–192.

[23] de Cabo R, Mattson MP. Effects of intermittent fasting on health and disease. N Engl J Med. 2019;381(26):2541–2551.

[24] Klement RJ. The emerging role of ketogenic diets in cancer treatment. Curr Opin Clin Nutr Metab Care. 2019;22(2):129–134.

[25] Seyfried TN, et al. Cancer as a metabolic disease. Carcinogenesis. 2014;35(3):515–527.

[26] Pantziarka P, et al. Repurposing drugs in oncology (ReDO). ecancermedicalscience. 2014;8:442.

[27] Pushpakom S, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.

[28] Ashrafizadeh M, et al. Curcumin in cancer therapy. J Cell Physiol. 2020;235(12):9247–9266.

[29] Gupta SC, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28(12):1937–1955.

[30] OneDayMD Editorial Team. Top 20 Alternative Cancer Treatments that Work: Evidence Based. OneDayMD. 2026.

[32] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.

[33] Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.

[34] Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy. Science. 2015;348(6230):56–61.

[35] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355.

[37] Greten FR, Grivennikov SI. Inflammation and cancer. Nature. 2019;574(7775):27–37.

[38] Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.

[39] Chang CH, et al. Metabolic competition in the tumor microenvironment. Cell. 2015;162(6):1229–1241.

[40] Ho PC, et al. Phosphoenolpyruvate is a metabolic checkpoint of T cell function. Cell. 2015;162(6):1217–1228.

[41] Gallagher EJ, LeRoith D. Insulin resistance in cancer. Endocr Relat Cancer. 2015;22(5):R211–R224.

[42] Giovannucci E, et al. Diabetes and cancer. Diabetes Care. 2010;33(7):1674–1685.

[51] Hulscher et al. Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. Zenodo Preprint. 2026.

[52] Bonaccio et al. Ultra-processed Food and Mortality among Long-Term Cancer Survivors from the Moli-sani Study. AACR Journal (Cancer Epidemiology, Biomarkers & Prevention). 2026.

[53] Hasenbohler et al. Intake of food additive preservatives and incidence of cancer: results from the NutriNet-Santé prospective cohort. BMJ. 2026.

[54] Lee et al. Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer. Nature Communications. 2026.

[55] Lane et al. Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses. BMJ. 2024.

[56] Huang et al. Dietary sugar consumption and health: umbrella review. BMJ. 2023.

[57] OneDayMD Editorial Team. Triple combination of Ivermectin, Mebendazole and Fenbendazole for Cancer: 16 Case Reports. OneDayMD. 2026.

[A] Juarez M, et al. Ivermectin and doxorubicin combination therapy activates microRNA Let-7 and induces cell death in PD-L1-positive breast cancer. NPJ Breast Cancer. 2021. doi:10.1038/s41523-021-00229-5.

[B] Bai R-Y, et al. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor growth in a model of prostate cancer. Br J Cancer. 2019. doi:10.1038/s41416-019-0681-5.

OneDayMD — Conventional medicine saves lives. Innovative and integrative approaches can extend and enhance them.

OneDayMD.com  |  Cancer.AestheticsAdvisor.com  |  Substack  |  About Us

© 2026 OneDayMD / One Day Media. All rights reserved. | Last Updated: June 21, 2026 | Version 3.0
This white paper is for educational purposes only and does not constitute medical advice. See full disclaimer above.